Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance vs Observation in CD20+ Lymphoma
NCT01933711Phase 3Unknown
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2002
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in aggressive B-cell lymphoma, mantle cell lymphoma (MCL), sponsored by Heidelberg University Hospital. Status: unknown.
02
Drugs
rituximab
03
Conditions
aggressive B-cell lymphomamantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01933711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933711.